Department of Neurology, Yerkes National Primate Research Center, Udall Center of Excellence for Parkinson's Disease, Emory University, Atlanta, Georgia, USA.
Centre for Molecular Medicine and Therapeutics at British Columbia Children's Hospital, The University of British Columbia, Vancouver, British Columbia, Canada.
Hum Gene Ther. 2021 Jun;32(11-12):599-615. doi: 10.1089/hum.2020.301. Epub 2021 Jun 1.
Viral vectors made from adeno-associated virus (AAV) have emerged as preferred tools in basic and translational neuroscience research to introduce or modify genetic material in cells of interest. The use of viral vectors is particularly attractive in nontransgenic species, such as nonhuman primates. Injection of AAV solutions into the cerebrospinal fluid is an effective method to achieve a broad distribution of a transgene in the central nervous system. In this study, we conducted injections of AAV9-PHP.B, a recently described AAV capsid mutant, in the lateral ventricle of mice and rhesus macaques. To enhance the expression of the transgene (the tag protein emerald green fluorescent protein [EmGFP]), we used a gene promoter that confers high neuron-specific expression of the transgene, the human synapsin 1 () promoter. The efficacy of the viral vector was first tested in mice. Our results show that intracerebroventricular injections of AAV9-PHP.B SYN1-EmGFP-woodchuck hepatitis virus posttranscriptional regulatory element resulted in neuronal EmGFP expression throughout the mice and monkey brains. We have provided a thorough characterization of the brain regions expressing EmGFP in both species. EmGFP was observed in neuronal cell bodies over the whole cerebral cortex and in the cerebellum, as well as in some subcortical regions, including the striatum and hippocampus. We also observed densely labeled neuropil in areas known to receive projections from these regions. Double fluorescence studies demonstrated that EmGFP was expressed by several types of neurons throughout the mouse and monkey brain. Our results demonstrate that a single injection in the lateral ventricle is an efficient method to obtain transgene expression in many cortical and subcortical regions, obviating the need of multiple intraparenchymal injections to cover large brain areas. The use of intraventricular injections of AAV9-PHP.B SYN1-EmGFP could provide a powerful approach to transduce widespread areas of the brain and may contribute to further development of methods to genetically target-specific populations of neurons.
腺相关病毒(AAV)制成的病毒载体已成为基础和转化神经科学研究中引入或修饰感兴趣细胞内遗传物质的首选工具。在非转基因物种(如非人类灵长类动物)中,病毒载体的使用特别有吸引力。将 AAV 溶液注入脑脊液是实现转基因在中枢神经系统中广泛分布的有效方法。在这项研究中,我们在小鼠和恒河猴的侧脑室中注射了最近描述的 AAV 衣壳突变体 AAV9-PHP.B。为了增强转基因的表达(标记蛋白翡翠绿色荧光蛋白[EmGFP]),我们使用了一种赋予转基因高度神经元特异性表达的基因启动子,即人类突触蛋白 1()启动子。该病毒载体的功效首先在小鼠中进行了测试。我们的结果表明,脑室内注射 AAV9-PHP.B SYN1-EmGFP-woodchuck 肝炎病毒转录后调控元件导致 EmGFP 在小鼠和猴脑中的神经元表达。我们已经对两种物种中表达 EmGFP 的脑区进行了全面描述。在整个大脑皮层和小脑中观察到 EmGFP 存在于神经元胞体中,以及一些皮质下区域,包括纹状体和海马体。我们还观察到在已知接收这些区域投射的区域中存在密集标记的神经突。双重荧光研究表明,EmGFP 在小鼠和猴脑中的多种神经元中表达。我们的结果表明,在侧脑室中进行单次注射是一种有效的方法,可以在许多皮质和皮质下区域获得转基因表达,避免了多次脑内注射以覆盖大的脑区。AAV9-PHP.B SYN1-EmGFP 的脑室注射可提供一种强大的方法来转导大脑的广泛区域,并可能有助于进一步开发针对特定神经元群体的基因靶向方法。